A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties.

Protein kinase-like domains that lack conserved residues known to catalyse phosphoryl transfer, termed pseudokinases, have emerged as important signalling domains across all kingdoms of life. Although predicted to function principally as catalysis-independent protein-interaction modules, several pseudokinase domains have been attributed unexpected catalytic functions, often amid controversy. We established a thermal-shift assay as a benchmark technique to define the nucleotide-binding properties of kinase-like domains. Unlike in vitro kinase assays, this assay is insensitive to the presence of minor quantities of contaminating kinases that may otherwise lead to incorrect attribution of catalytic functions to pseudokinases. We demonstrated the utility of this method by classifying 31 diverse pseudokinase domains into four groups: devoid of detectable nucleotide or cation binding; cation-independent nucleotide binding; cation binding; and nucleotide binding enhanced by cations. Whereas nine pseudokinases bound ATP in a divalent cation-dependent manner, over half of those examined did not detectably bind nucleotides, illustrating that pseudokinase domains predominantly function as non-catalytic protein-interaction modules within signalling networks and that only a small subset is potentially catalytically active. We propose that henceforth the thermal-shift assay be adopted as the standard technique for establishing the nucleotide-binding and catalytic potential of kinase-like domains.

[1]  G. Drewes,et al.  Affinity profiling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP. , 2013, ACS chemical biology.

[2]  Paul T. Tarr,et al.  An Evolutionarily Conserved Pseudokinase Mediates Stem Cell Production in Plants , 2011, Plant Cell.

[3]  J. Yates,et al.  Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression , 2010, Proceedings of the National Academy of Sciences.

[4]  Gerard Manning,et al.  Structural and Functional Diversity of the Microbial Kinome , 2007, PLoS biology.

[5]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[6]  M. Lemmon,et al.  Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family , 2012, The Biochemical journal.

[7]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[8]  R. Bamert,et al.  Production and crystallization of recombinant JAK proteins. , 2013, Methods in molecular biology.

[9]  Ji Luo,et al.  Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis , 2012, Proceedings of the National Academy of Sciences.

[10]  P. McPherson,et al.  Scyl1, Mutated in a Recessive Form of Spinocerebellar Neurodegeneration, Regulates COPI-mediated Retrograde Traffic*♦ , 2008, Journal of Biological Chemistry.

[11]  Tony Pawson,et al.  Temporal regulation of EGF signaling networks by the scaffold protein Shc1 , 2013, Nature.

[12]  W. Alexander,et al.  Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL. , 2014, The Biochemical journal.

[13]  D. V. van Aalten,et al.  Pseudokinases-remnants of evolution or key allosteric regulators? , 2010, Current opinion in structural biology.

[14]  Stefan Knapp,et al.  Structure of the Pseudokinase VRK3 Reveals a Degraded Catalytic Site, a Highly Conserved Kinase Fold, and a Putative Regulatory Binding Site , 2009, Structure.

[15]  Alma L. Burlingame,et al.  A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK , 2011, Nature.

[16]  J. Kuriyan,et al.  The Conformational Plasticity of Protein Kinases , 2002, Cell.

[17]  G. Martin,et al.  Xanthomonas T3S Effector XopN Suppresses PAMP-Triggered Immunity and Interacts with a Tomato Atypical Receptor-Like Kinase and TFT1[W] , 2009, The Plant Cell Online.

[18]  Jonathan Bard,et al.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.

[19]  D. Goeddel,et al.  Membrane guanylate cyclase is a cell-surface receptor with homology to protein kinases , 1988, Nature.

[20]  J. Boothroyd,et al.  Bradyzoite Pseudokinase 1 Is Crucial for Efficient Oral Infectivity of the Toxoplasma gondii Tissue Cyst , 2013, Eukaryotic Cell.

[21]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[22]  G. Labesse,et al.  ROP2 from Toxoplasma gondii: a virulence factor with a protein-kinase fold and no enzymatic activity. , 2008, Structure.

[23]  Maria Deak,et al.  Structure of the LKB1-STRAD-MO25 Complex Reveals an Allosteric Mechanism of Kinase Activation , 2009, Science.

[24]  Marc Vidal,et al.  COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation , 2010, Nature.

[25]  John Kuriyan,et al.  Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 , 2009, Proceedings of the National Academy of Sciences.

[26]  A. R. Shenoy,et al.  The kinase homology domain of receptor guanylyl cyclase C: ATP binding and identification of an adenine nucleotide sensitive site. , 2006, Biochemistry.

[27]  S. Nelson,et al.  SGK196 Is a Glycosylation-Specific O-Mannose Kinase Required for Dystroglycan Function , 2013, Science.

[28]  A. Fraser,et al.  Nuclear receptor binding protein 1 regulates intestinal progenitor cell homeostasis and tumour formation , 2012, The EMBO journal.

[29]  Qingshan Li,et al.  Identification of an Acquired JAK2 Mutation in Polycythemia Vera* , 2005, Journal of Biological Chemistry.

[30]  Toru Okamoto,et al.  The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. , 2013, Immunity.

[31]  H C Clevers,et al.  Activation of the tumour suppressor kinase LKB1 by the STE20‐like pseudokinase STRAD , 2003, The EMBO journal.

[32]  Chae Un Kim,et al.  Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases , 2013, Nature Structural &Molecular Biology.

[33]  L. Berg,et al.  A new member of the Eph family of receptors that lacks protein tyrosine kinase activity. , 1996, Oncogene.

[34]  R. Norton,et al.  Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. , 2012, Immunity.

[35]  G. Stark,et al.  IRAK-M Is a Novel Member of the Pelle/Interleukin-1 Receptor-associated Kinase (IRAK) Family* , 1999, The Journal of Biological Chemistry.

[36]  Ying Jin,et al.  Deletion of STK40 Protein in Mice Causes Respiratory Failure and Death at Birth* , 2013, The Journal of Biological Chemistry.

[37]  R. Radhakrishnan,et al.  ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation , 2010, Proceedings of the National Academy of Sciences.

[38]  M. Mann,et al.  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. , 2008, Molecular cell.

[39]  J. Boothroyd,et al.  A Toxoplasma gondii Pseudokinase Inhibits Host IRG Resistance Proteins , 2012, PLoS biology.

[40]  Yibing Shan,et al.  Crystal structures of the Jak2 pseudokinase domain and the pathogenic mutant V617F , 2012, Nature Structural &Molecular Biology.

[41]  T. Südhof,et al.  CASK Functions as a Mg2+-Independent Neurexin Kinase , 2008, Cell.

[42]  M. Lemmon,et al.  Receptor tyrosine kinases with intracellular pseudokinase domains. , 2013, Biochemical Society transactions.

[43]  P. Eyers,et al.  Dawn of the dead: protein pseudokinases signal new adventures in cell biology. , 2013, Biochemical Society transactions.

[44]  S. Knapp,et al.  Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.

[45]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[46]  C. Gee,et al.  A Phosphorylated Pseudokinase Complex Controls Cell Wall Synthesis in Mycobacteria , 2012, Science Signaling.

[47]  Naveid A Ali,et al.  Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway. , 2013, Cancer research.

[48]  Jihwan Song,et al.  Cloning and characterization of the full-length mouse Ptk7 cDNA encoding a defective receptor protein tyrosine kinase. , 2004, Gene.

[49]  J. Qin,et al.  Biochemical, Proteomic, Structural, and Thermodynamic Characterizations of Integrin-linked Kinase (ILK) , 2011, The Journal of Biological Chemistry.

[50]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[51]  Florian Gnad,et al.  Large-scale Proteomics Analysis of the Human Kinome , 2009, Molecular & Cellular Proteomics.

[52]  James M. Murphy,et al.  In vitro JAK kinase activity and inhibition assays. , 2013, Methods in molecular biology.

[53]  L. Trusolino,et al.  ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis , 2011, BMC Proceedings.

[54]  C. Hovens,et al.  RYK, a receptor tyrosine kinase-related molecule with unusual kinase domain motifs. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Eduardo Pauls,et al.  Two Phases of Inflammatory Mediator Production Defined by the Study of IRAK2 and IRAK1 Knock-in Mice , 2013, The Journal of Immunology.

[56]  H. Matsuoka,et al.  Expression of a kinase-defective Eph-like receptor in the normal human brain. , 1997, Biochemical and biophysical research communications.

[57]  O. Silvennoinen,et al.  Regulation of the Jak2 Tyrosine Kinase by Its Pseudokinase Domain , 2000, Molecular and Cellular Biology.

[58]  S. Hubbard,et al.  The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling , 2011, Nature Structural &Molecular Biology.

[59]  D. Hilton,et al.  A convenient method for preparation of an engineered mouse interleukin-3 analog with high solubility and wild-type bioactivity , 2010, Growth factors.

[60]  Sharmeela Kaushal,et al.  KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. , 2012, Cancer research.

[61]  T. Roberts,et al.  The conserved lysine of the catalytic domain of protein kinases is actively involved in the phosphotransfer reaction and not required for anchoring ATP. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Stewart,et al.  TNP-ATP and TNP-ADP as probes of the nucleotide binding site of CheA, the histidine protein kinase in the chemotaxis signal transduction pathway of Escherichia coli. , 1998, Biochemistry.

[63]  S. Blacklow,et al.  Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding. , 2010, Blood.

[64]  Bernhard Kuster,et al.  Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.

[65]  Mathijs Vleugel,et al.  The vertebrate mitotic checkpoint protein BUBR1 is an unusual pseudokinase. , 2012, Developmental cell.

[66]  J. Qin,et al.  The pseudoactive site of ILK is essential for its binding to alpha-Parvin and localization to focal adhesions. , 2009, Molecular cell.

[67]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[68]  J. Boothroyd,et al.  A Conserved Non-canonical Motif in the Pseudoactive Site of the ROP5 Pseudokinase Domain Mediates Its Effect on Toxoplasma Virulence* , 2011, The Journal of Biological Chemistry.

[69]  G. Barton,et al.  Emerging roles of pseudokinases. , 2006, Trends in cell biology.

[70]  R. Fässler,et al.  Integrin-linked kinase is an adaptor with essential functions during mouse development , 2009, Nature.

[71]  B. Druker,et al.  Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. , 2012, Cancer cell.

[72]  D. V. van Aalten,et al.  ATP and MO25α Regulate the Conformational State of the STRADα Pseudokinase and Activation of the LKB1 Tumour Suppressor , 2009, PLoS biology.

[73]  Chao Zhang,et al.  Structure and substrate recruitment of the human spindle checkpoint kinase Bub1. , 2008, Molecular cell.

[74]  Osamu Takeuchi,et al.  Sequential control of Toll-like receptor–dependent responses by IRAK1 and IRAK2 , 2008, Nature Immunology.

[75]  H. Lee,et al.  Characterization of the human full-length PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule closely related to chick KLG. , 1996, Journal of biochemistry.

[76]  I. Lucet,et al.  Techniques to examine nucleotide binding by pseudokinases. , 2013, Biochemical Society transactions.